Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Pemetrexed in NSCLC Patients With Stable Brain Metastases
NCT00227019Phase 2Completed
- Sponsor
- Heather Wakelee
- Start
- Mar 2006
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Heather Wakelee. Primary endpoint: Incidence of Central Nervous System (CNS) Hemorrhagic Events at 18 months. Started Mar 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00227019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227019.